A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Starting soon

Conditions studied: Breast Cancer

In brief

A Multicenter, Observational Study on the Real-World Effectiveness and Safety of inavolisib Combined with Endocrine Therapy With or Without a CDK4/6 Inhibitor in Patients with HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer.

Key facts

Study ID

NCT07543250

Run by

xuliang

People needed

100

Starts

2026-05-16

Expected to finish

2027-07-30

Last updated by the study team

2026-04-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed HR+/HER2- recurrent or metastatic breast cancer.
• Presence of a pathogenic PIK3CA mutation confirmed by tissue or plasma-based NGS/PCR testing.
• Availability of traceable electronic medical records, imaging, laboratory, and follow-up data at baseline.
• Initiated treatment with "Inavolisib + Endocrine Therapy" with or without a CDK4/6 inhibitor in real-world clinical practice, with complete and traceable regimen information.
• Provision of informed consent for this non-interventional study (if required by the center's ethics committee).

You may not qualify if…

• Concurrent participation in any interventional clinical trial at enrollment.
• Presence of another active malignancy requiring concurrent systemic therapy, or missing core data preventing outcome assessment.
• Any condition (psychiatric, social, geographical) that would preclude adequate follow-up, as judged by the investigator.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.